MarketInOut Stock Screener Log In | Sign Up

Nautilus Biotechnology Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Nautilus Biotechnology Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization399.95 mln
Float73.90 mln
Earnings Date03/04/2027

Piotroski F-Score

3 / 9
Below average

Relative Strength

99 / 100
Top performer

Debt / Equity

0.23
Very low leverage

Pre-Tax Margin

-13,817%
Severely loss-making

ROE

-40.78
Deeply negative

Altman Z-Score

3.39
Sound

Business Description

Founded in 2016 and based in Seattle, Washington, Nautilus Biotechnology is an early-stage life sciences company building a technology platform designed to measure and analyze proteins at a highly detailed level. Its core product, the Nautilus Voyager Platform, combines specialized instruments, chemical reagents, and software to identify and quantify proteins found in biological samples. The company has established research partnerships with leading institutions including Genentech, Cornell University, and the Michael J. Fox Foundation to advance its work.

Key Fundamentals

EPS-0.46
ROE-40.78
RPS0.00
ROIC-80.13
ROA-33.20
EBITDA, mln-52.93
EV / EBITDA-6.72
EV / EBIT-6.08
Revenue, mln0.42
EV / Revenue839

Quote Details

Last 2.73
Change -0.41 (-13.06%)
Open 2.88
Volume 8,034,636
Turnover 21,934,556
Average Volume 12,101,762

Financial Ratios

Pre-Tax Profit Margin-13,817
Leverage Ratio1.28
Current Ratio9.25
Price / Book3.55
Price / Tangible Book3.55
Debt / Equity0.23
Price / Sales1,088

Financial Strength

Altman Z-Score3.39
Piotroski F-Score 3 / 9
Short Ratio0.69
Short % of Float8.96

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -15.74% 6 / 100   
1 Month 73.89% 99 / 100   
2 Months 64.46% 98 / 100   
6 Months 1.11% 60 / 100   
1 Year 93.62% 97 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog